Drug Manufacture Progress in MorphoSys’ Phase 3 Myelofibrosis Program.By MohamedMis2July 17, 2023 MorphoSys, the German biotech company, has delivered positive news to its shareholders. The Phase 3 myelofibrosis program is progressing 16%…
Financial MorphoSys Raises Q2 & FY22 GuidanceBy MohamedMis2July 12, 2023 MorphoSys, a leading biotechnology company, has recently announced updates to its Q2 and FY22 guidance levels. Revealing higher projections than…
Drug Manufacture MorphoSys Awaits Pivotal Phase 3 Clinical DataBy MohamedMis2July 11, 2023 In a highly anticipated move, JP Morgan analyst Michael Nuen suggests that MorphoSys, the German biotech company, could experience a…
